First Pfizer Pharmaceutical Company Trial Authorized With a Median of 8.2 Weeks Using the FAST TRACK Evaluation Service 


For the first time, the Pfizer pharmaceutical company used CATALIS’ FAST TRACK Evaluation Service to authorize a complex Phase Ia/Ib oncology clinical trial, meaning a master protocol that includes several sub-studies.

In this study, Pfizer is assessing the effectiveness of a potential treatment for patients with advanced solid tumours. Phase Ia is being conducted at a dozen sites and aims to recruit 40 patients worldwide.

Thanks to CATALIS’ FAST TRACK Evaluation Service, three Quebec healthcare institutions were able to authorize the clinical trial with a median of 8.2 weeks, ranking one of them among the 3rd fastest activated sites in the world.




“Pfizer is pleased to be a member of the CATALIS Network and to have carried out its first project through the FAST TRACK Evaluation Service. Given the critical need to offer new treatments to patients more quickly, the FAST TRACK Evaluation Service allowed us to significantly reduce the time it took us to launch our study while greatly simplifying the logistics inherent in the process. We really hope to repeat this success in future collaborations with the CATALIS Evaluation Service.”  Mona Maroun, Director, Clinical Site Management, Pfizer Canada


The main site, the CHU de Québec-Université Laval, authorized the clinical trial in 8.2 weeks, ranking it 3rd in the world and 1st in Canada out of all sites activated for this study.


“The CHU de Québec-Université Laval is proud to have participated in CATALIS’ FAST TRACK Evaluation Service since this initiative’s inception. By activating clinical trials faster, we are giving ourselves the opportunity to have quicker access to innovative new therapeutic approaches for the benefit of all our patients. In addition, our participation in CATALIS’ FAST TRACK Evaluation Service lets us showcase our clinical research teams’ skills and expertise.” – Dr. Stéphane Bolduc, assistant director of clinical research, CHU de Québec-Université Laval 



The McGill University Health Centre (MUHC) also authorized this Phase 1a/1b oncology study in 7.0 weeks, making it the 2nd activated site in Canada. Montréal’s Jewish General Hospital authorized this study in 9.8 weeks.


If you are a pharmaceutical company and would like to learn more about this service, please write to us at: